公开(公告)号：US06506877B1

公开(公告)日：2003-01-14

申请号：US08583153

申请日：1995-12-28

Applicant: Louis A Tartaglia ,  Robert I Tepper ,  Janice A Culpepper

Inventor： Louis A Tartaglia ,  Robert I Tepper ,  Janice A Culpepper

IPC: C07K1471

CPC classification number: C07K14/715 ,  A61K38/00 ,  C07K2319/00

Abstract: The present invention relates to the discovery, identification and characterization of nucleotides that encode Ob receptor (ObR), a receptor protein that participates in mammalian body weight regulation. The invention encompasses obR nucleotides, host cell expression systems, ObR proteins, fusion proteins, polypeptides and peptides, antibodies to the receptor, transgenic animals that express an obR transgene, or recombinant knock-out animals that do not express the ObR, antagonists and agonists of the receptor, and other compounds that modulate obR gene expression or ObR activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of body weight disorders, including but not limited to obesity, cachexia and anorexia.

Abstract translation: 本发明涉及编码参与哺乳动物体重调节的受体蛋白Ob受体（ObR）的核苷酸的发现，鉴定和表征。 本发明包括obR核苷酸，宿主细胞表达系统，ObR蛋白，融合蛋白，多肽和肽，受体抗体，表达obR转基因的转基因动物或不表达ObR的拮抗剂和激动剂的重组敲除动物 的受体和调节可用于诊断，药物筛选，临床试验监测和/或治疗体重障碍（包括但不限于肥胖，恶病质和厌食）的obR基因表达或ObR活性的其它化合物。

公开(公告)号：US06504007B1

公开(公告)日：2003-01-07

申请号：US08860370

申请日：1997-06-06

Applicant: Robert D. Klein ,  Mark W. Moore ,  Arnon Rosenthal ,  Anne M. Ryan

Inventor： Robert D. Klein ,  Mark W. Moore ,  Arnon Rosenthal ,  Anne M. Ryan

IPC: C07K1471

CPC classification number: C07K14/71 ,  A01K2217/05 ,  A61K38/00 ,  C07K16/22 ,  C07K2319/00

Abstract: GDNFR&agr;, GDNFR&agr; extracellular domain (ECD), GDNFR&agr; variants, chimeric GDNFRae (e.g., GDNFR&agr; immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to GDNFR&agr;-ligands, for example GDNF, by providing GDNFR&agr; to the cell. Also provided are methods for using GDNFR&agr;, GDNF, or agonists thereof, separately or in complex, to treat kidney diseases.

Abstract translation: 公开了GDNFRalpha，GDNFRalpha细胞外结构域（ECD），GDNFRalpha变体，嵌合GDNFRae（例如GDNFRα免疫粘附素）和与其结合的抗体（包括激动剂和中和抗体）。 描述了这些分子的各种用途，包括通过向细胞提供GDNFRα来调节对GDNFRα-配体（例如GDNF）的响应来调节细胞活性和存活的方法。 还提供了分别或复合的使用GDNFRalpha，GDNF或其激动剂来治疗肾脏疾病的方法。

公开(公告)号：US06599717B1

公开(公告)日：2003-07-29

申请号：US09677046

申请日：2000-09-29

Applicant: Allen James Ebens, Jr. ,  R. Glenn Hammonds ,  Jonathan C. Heller ,  Greg Weddell ,  John W. Winslow

Inventor： Allen James Ebens, Jr. ,  R. Glenn Hammonds ,  Jonathan C. Heller ,  Greg Weddell ,  John W. Winslow

IPC: C07K1471

CPC classification number: C07K14/71

Abstract: Vascular Endothelial Growth Factor Receptor (dmVEGFR) nucleic acids and proteins that have been isolated from Drosophila melanogaster are described. The dmVEGFR nucleic acids and proteins can be used to genetically modify metazoan invertebrate organisms, such as insects and worms, or cultured cells, resulting in dmVEGPR expression or mis-expression. The genetically modified organisms or cells can be used in screening assays to identify candidate compounds which are potential therapeutics that interact with dmVEGFR protein. They can also be used in methods for studying dmVEGFR activity and identifying other genes that modulate the function of, or interact with, the dmVEGFR gene.

Abstract translation: 描述了已经从黑腹果蝇分离的血管内皮生长因子受体（dmVEGFR）核酸和蛋白质。 dmVEGFR核酸和蛋白质可用于遗传修饰后生动物无脊椎动物，如昆虫和蠕虫，或培养细胞，导致dmVEGPR表达或错误表达。 遗传修饰的生物体或细胞可用于筛选试验以鉴定与dmVEGFR蛋白相互作用的潜在治疗剂的候选化合物。 它们也可用于研究dmVEGFR活性的方法，并鉴定调节dmVEGFR基因功能或与之相互作用的其他基因。

公开(公告)号：US06590074B1

公开(公告)日：2003-07-08

申请号：US08756031

申请日：1996-11-26

Applicant: John S. O'Brien ,  Yasuo Kishimoto

Inventor： John S. O'Brien ,  Yasuo Kishimoto

IPC: C07K1471

CPC classification number: E03B7/074 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/0051 ,  A61K9/0085 ,  A61K9/127 ,  A61K9/19 ,  A61K38/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/475 ,  C07K14/52 ,  C07K14/705 ,  C07K14/71 ,  C07K14/715 ,  Y02A50/465

Abstract: Prosaposin, saposin C and various peptide fragments of saposin C stimulate neurite outgrowth in vitro. In addition, prosaposin and saposin C promote increased myelination ex vivo. Prosaposin is present in large neurons of the brain, including both upper and lower motor neurons.

Abstract translation: 皂角苷C和皂角苷C的各种肽片段在体外刺激神经突生长。 此外，赞子和皂角蛋白C促进离体髓鞘形成。 普罗沙星存在于脑的大神经元中，包括上部和下部运动神经元。

公开(公告)号：US06384191B1

公开(公告)日：2002-05-07

申请号：US07834311

申请日：1992-02-13

Applicant: Lewis T. Williams ,  Daniel E. Johnson ,  Pauline E Lee

Inventor： Lewis T. Williams ,  Daniel E. Johnson ,  Pauline E Lee

IPC: C07K1471

CPC classification number: C07K14/71 ,  A61K38/00 ,  G01N33/74 ,  G01N2333/50 ,  G01N2333/71 ,  G01N2500/00

Abstract: A fibroblast growth factor (FGF) receptor including a basic fibroblast growth factor receptor has been purified. Various forms have been identified including soluble forms lacking any transmembrane segment. DNA sequences encoding full-length fibroblast growth factor receptors and polypeptides comprising a portion of an FGF-R ligand-binding domain have been isolated and sequenced. These DNAs include DNAs encoding for a basic FGF-R and a human FGF-R and are operably linked to control sequences and expressed in a culture of a compatible host transformed, transfected or electroporated by a cloning vehicle containing the DNA sequence. The invention also comprises antibodies to the receptor, methods of synthesizing the growth factor receptor proteins, methods for providing analogs of the fibroblast growth factor receptors. Methods for evaluating compositions which promote or inhibit fibroblastic growth factors and compositions which are agonistic or antagonistic to fibroblast growth factor receptors are also provided. Diagnostic and therapeutic uses are described.

Abstract translation: 已经纯化了包含碱性成纤维细胞生长因子受体的成纤维细胞生长因子（FGF）受体。 已经鉴定了各种形式，包括不含任何跨膜片段的可溶形式。 已经分离并测序了编码全长成纤维细胞生长因子受体的DNA序列和包含一部分FGF-R配体结合结构域的多肽。 这些DNA包括编码碱性FGF-R和人FGF-R的DNA，并且与对照序列可操作地连接，并在通过含有DNA序列的克隆载体转化，转染或电穿孔的相容宿主的培养物中表达。 本发明还包括对受体的抗体，合成生长因子受体蛋白质的方法，提供成纤维细胞生长因子受体类似物的方法。 还提供了评估促进或抑制成纤维细胞生长因子的组合物和对成纤维细胞生长因子受体具有激动作用或拮抗作用的组合物的方法。 描述诊断和治疗用途。

公开(公告)号：US06359115B1

公开(公告)日：2002-03-19

申请号：US09483539

申请日：2000-01-14

Applicant: Richard L. Kendall ,  Xianzhi Mao ,  Kenneth A. Thomas ,  Andrew Tebben

Inventor： Richard L. Kendall ,  Xianzhi Mao ,  Kenneth A. Thomas ,  Andrew Tebben

IPC: C07K1471

CPC classification number: C07K14/71 ,  C07K2319/00 ,  G01N2333/71

Abstract: An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.

Abstract translation: 公开了编码新型人受体型酪氨酸激酶基因KDR的分离的核酸分子。 该KDR cDNA序列的分离导致纯化形式的人类KDR蛋白，重组载体和表达人类KDR的重组宿主的公开。

公开(公告)号：US06348333B1

公开(公告)日：2002-02-19

申请号：US09142956

申请日：1999-03-04

Applicant: Mikio Niwa ,  Masaji Okamoto ,  Tomoe Matsumoto ,  Toshiaki Segawa

Inventor： Mikio Niwa ,  Masaji Okamoto ,  Tomoe Matsumoto ,  Toshiaki Segawa

IPC: C07K1471

CPC classification number: C07K14/70503 ,  A61K38/00 ,  C07K14/71 ,  C07K2319/00 ,  C07K2319/30

Abstract: A novel polypeptide is provided, which can be utilized to treat diseases accompanying neovascularization, such as solid tumors, and is useful as a low molecular weight VEGF inhibitor. The polypeptide contains immunoglobulin-like domain 1 and immunoglobulin-like domain 2 of the extracellular domain of the VEGF receptor KDR. Since it has smaller molecular weight than the conventional polypeptides with retaining VEGF inhibitory activity, it is expected that it can be readily expressed using recombinant DNA techniques and infiltrates into diseased sites more quickly.

Abstract translation: 提供了新的多肽，其可用于治疗伴随新生血管形成的疾病，例如实体瘤，并且可用作低分子量VEGF抑制剂。 该多肽包含VEGF受体KDR的细胞外结构域的免疫球蛋白样结构域1和免疫球蛋白样结构域2。 由于其具有比具有保留VEGF抑制活性的常规多肽更小的分子量，因此预期其可以使用重组DNA技术容易地表达并更快地渗透到患病部位。